Phase 2 N=11 AZD8601 Study in CABG Patients
Heart Failure
Primary: Number of Subjects With Adverse Events — 7; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=26 A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
Alzheimer Disease · Cognitive Dysfunction · Mild Dementia
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 7 Participants
Phase 2 N=58 NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer
Rectal Cancer
Primary: Percentage of Organ Preservation — 57 percentage of participants
Phase 2 N=64 Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT
Diffuse Large B-Cell Lymphoma
Primary: Overall Response (OR) Rate — 36 Participants
Phase 2 N=48 Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma
Pancreatic Cancer · Periampullary Adenocarcinoma
Primary: Late Gastrointestinal Toxicities — 13 Participants
Phase 2 N=21 Enhancing Prolonged Exposure With Cannabidiol to Treat Posttraumatic Stress Disorder
Posttraumatic Stress Disorder · Stress Disorders, Post-Traumatic
Primary: Clinician Administered PTSD Scale (CAPS-5) — 42.8; 42.9; 15.2; 10.1 score on a scale
Phase 2 N=24 Treg Modulation With CD28 and IL-6 Receptor Antagonists
Living-Donor Kidney Transplant · Kidney Transplant Recipients
Primary: The Proportion of Participants Who Remain Free of Biopsy-proven Acute T-cell Mediated or Antibody-mediated Rejection (as Defined by Banff Criteria) at 6 Months…
Phase 2 N=166 Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults
Cystic Fibrosis
Primary: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1%) — -1.1774; -1.9489; -0.5417; -1.5470 Change in FEV1 % predicted — p=0.3449
Phase 2 N=124 Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years
SARS-CoV-2 Infection, COVID19
Primary: Geometric Mean Titers (GMTs) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Neutralizing Titers at 1 Month After Vaccination 3 in Participants Aged >=2…
Phase 2 N=41 Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
Malignant Pleural Mesothelioma
Primary: 1-year Progression-free Survival — 44; 33 percentage of participants
Phase 2 N=317 A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
Alopecia Areata
Primary: Part A, Period 2: Percentage of Participants Achieving Loss of Regrowth Maintenance (LOM) Criteria Defined by Severity of Alopecia Tool (SALT) Score > 20 Following Dose…
Phase 2 N=499 A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity
Obesity
Primary: Cohorts 1 and 2: Percent Change From Baseline in Body Weight at End of Treatment at Week 26 — 0.17; -5.43; -4.83; -8.94 Percent change — p=<.0001
Phase 2 N=12 A Safety Study of Intravitreal PP-001 in Patients With Chronic, Non-Infectious Uveitis
Non-infectious Uveitis
Primary: Evaluation of Safety and Tolerability by Determining Treatment Emergent Adverse Events — 12 Participants
Phase 2 N=40 Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis
Non-small Cell Lung Cancer Stage IV
Primary: Efficacy of Atezolizumab + CBDCA + Pemetrexed by Evaluating PFS Rate — 62.2 percentage of participants
Phase 2 N=11 Study of TVEC in Patients With Cutaneous Squamous Cell Cancer
Squamous Cell Carcinoma · Skin Cancer · Keratoacanthoma
Primary: Overall Response Rate — 11; 1; 10 Participants — p=0.0005